Services
Partnering intelligence backed by deep scientific and healthcare expertise. From evidence synthesis and health economic modeling to deal sourcing and facilitation — we deliver the full stack of capabilities pharma and biotech need to close deals.
Powered by MarksMan Healthcare Communications
A 12-month productized engagement: 90+ structured deliverables/year, 4 conferences covered live, asset evaluation across 8 dimensions, hands-on deal facilitation, and a dedicated platform copilot — all calibrated to one geography of your choice.
We map the global biotech landscape against your BD thesis — by therapeutic area, clinical stage, modality, and geography. From China and India to APAC and emerging markets, we bring regional context, regulatory insight, and local networks that global BD teams typically lack.
Structured analysis of recent licensing deals, M&A transactions, and comparable partnerships in your therapeutic area. Know what the market is paying before you negotiate.
Pre-conference intelligence packages: priority target lists, meeting scheduling, counterpart dossiers, and structured follow-up. For BIO International, BioChina, BIO-Europe, CPHI, and beyond. We are there — so you don't have to waste time on the wrong meetings.
As discussions progress, we support with evidence review, term benchmarking, and facilitation. Deal-ready packages shorten diligence cycles. We stay in the loop until close.
We sharpen your narrative into the Problem-Patient-Proof framework that pharma BD teams and investors expect. Your science, reframed for the audience that matters.
Non-confidential deck development, partner target lists, and positioning strategy. Everything you need to walk into BD conversations prepared.
Curated, evidence-backed outreach to the specific pharma companies and investors most likely to care about your asset. Not volume spray — targeted engagement.
We represent your asset at major conferences. Pre-scheduled meetings with pharma BD teams, counterpart dossiers, and structured follow-up — so your science gets seen without burning $50K on a booth.
We bring the rigour of delivering HEOR, competitive intelligence, and evidence strategy to the world's largest pharma companies — now repackaged for small biotechs. The ones that need it most but can afford it least.
Pharma won't look at your asset if you can't show a cost-effectiveness story. We build early-stage models that demonstrate commercial viability — before you even start partnering conversations.
Where does your asset sit vs. competitors? We map the landscape — pipeline threats, recent deals, comparable transactions — so you walk into every BD meeting knowing exactly where you stand.
Great science isn't enough — pharma needs to understand it in 5 minutes. We identify your evidence gaps, reframe your asset into the language BD teams respond to, and deliver a complete readiness package that turns scientific potential into deal-ready positioning.
Published evidence is the currency of credibility. We support your publication strategy end-to-end — from identifying high-impact journals to drafting manuscripts, conference abstracts, and white papers that build the scientific narrative pharma and investors need to see.
These services are delivered by the same team that has served top-20 pharma companies worldwide. Now available to small biotechs at a fraction of the cost.
Engagement Models
We do not believe in one-size-fits-all. Our engagement models are designed to match where you are and what you need.
Ongoing access to our intelligence layer and deal support. Ideal for pharma BD teams running continuous scouting programs across multiple therapeutic areas.
Focused engagements with clear deliverables and timelines. Evidence blueprints, positioning strategy, or targeted scouting — delivered in weeks, not quarters.
We invest our time and network in your asset. Our fee is tied to outcomes — we earn when a deal or investment closes through our introductions.
Why ForesightRx
Not a static database. Our intelligence is continuously updated from 12+ global conferences annually. Every meeting feeds the engine.
Every recommendation backed by clinical, competitive, and commercial evidence. We bring the rigour pharma expects.
45+ markets tracked. Deep networks across China, India, APAC, and global pharma. We bridge ecosystems others miss.
We don't stop at reports. We position, introduce, facilitate, and support through to deal close.
Every engagement starts with a conversation. No commitment, no sales pitch — just an honest assessment of whether there is a fit.
Start a Conversation